Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis

New regimens based on two or more novel agents are sought to shorten or simplify treatment of tuberculosis (TB). Pretomanid (PMD) is a nitroimidazole in phase 3 trials that has significant bactericidal activity alone and in combination with bedaquiline (BDQ) and/or pyrazinamide (PZA). We previously...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Tasneen, Rokeya, Betoudji, Fabrice, Tyagi, Sandeep, Li, Si-Yang, Williams, Kathy, Converse, Paul J., Dartois, Véronique, Yang, Tian, Mendel, Carl M., Mdluli, Khisimuzi E., Nuermberger, Eric L.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2015
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704221/
https://ncbi.nlm.nih.gov/pubmed/26503656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01691-15
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars